Sources: OpenAI told investors the company expects $200M revenue in 2023 and $1B by 2024; source: OpenAI was recently valued at $20B in a secondary share sale
how much revenue will your parent company @OpenAI generate? And we've got some pretty ambitious numbers from the company's pitch deck to investors. w/@JLDastin @peard33 https://www.reuters.com/...
Context & Ripple Effects
OpenAI's late-2022 investor deck established the baseline every later number gets measured against: $200M expected revenue for 2023 and $1B by 2024, priced off a $20B secondary share sale. At the time, the deck was the clearest public signal that a research lab intended to become a revenue business.
The arc since then makes the deck look conservative: monthly revenue roughly doubled in the first seven months of 2025 alone, hitting $12B annualized, and by mid-2026 the company was running at $40B+ annualized — while separately projecting $280B in revenue by 2030. Each successive disclosure repriced the same asset the 2022 secondary first marked.
First-order effects
- Employees selling shares in the $20B secondary are accepting a price equal to roughly 100x OpenAI's own $200M 2023 forecast and 20x its $1B 2024 target — liquidity now, contingent on the deck's growth curve holding.
- Investors buying into the secondary gain a benchmarked data point: OpenAI's disclosed revenue targets give them the first concrete basis for underwriting an AI lab on revenue rather than research promise.
Second-order effects
- Rival AI labs pitching their own fundraises must now answer OpenAI's published trajectory, forcing their investor materials to justify comparable multiples without equivalent commercial traction.
Third-order effects
- If the pattern holds — each forecast beaten, each disclosure lifting the next valuation — AI-lab capital markets shift toward pricing projected rather than trailing revenue, making forward guidance itself the core financing instrument.
The trend: AI labs are turning revenue forecasts into financing events, with secondary-market valuations repricing faster on projected growth curves than on reported results.